Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $12.0 in the prior trading day, Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $12.18, up 1.50%. In other words, the price has increased by $1.50 from its previous closing price. On the day, 1.5 million shares were traded. AMRX stock price reached its highest trading level at $12.3 during the session, while it also had its lowest trading level at $12.06.
Ratios:
Our goal is to gain a better understanding of AMRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.34. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 2.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On February 24, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $9 to $12.
JP Morgan Upgraded its Underweight to Neutral on September 06, 2024, while the target price for the stock was maintained at $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Nark Ted C sold 50,000 shares for $11.72 per share. The transaction valued at 586,000 led to the insider holds 291,029 shares of the business.
Nark Ted C bought 50,000 shares of AMRX for $591,250 on Nov 17 ’25. On Nov 12 ’25, another insider, Shah Nikita, who serves as the Executive Vice President of the company, sold 131,856 shares for $11.92 each. As a result, the insider received 1,571,724 and left with 146,403 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 3828940288 and an Enterprise Value of 6378472448. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 857.75, and their Forward P/E ratio for the next fiscal year is 12.92. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 32.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.30. Its current Enterprise Value per Revenue stands at 2.173 whereas that against EBITDA is 10.225.
Stock Price History:
The Beta on a monthly basis for AMRX is 1.35, which has changed by 0.39049828 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, AMRX has reached a high of $12.68, while it has fallen to a 52-week low of $6.68. The 50-Day Moving Average of the stock is 11.84%, while the 200-Day Moving Average is calculated to be 36.41%.
Shares Statistics:
The stock has traded on average 1.71M shares per day over the past 3-months and 1688210 shares per day over the last 10 days, according to various share statistics. A total of 314.31M shares are outstanding, with a floating share count of 156.64M. Insiders hold about 50.17% of the company’s shares, while institutions hold 44.16% stake in the company. Shares short for AMRX as of 1763078400 were 6575260 with a Short Ratio of 3.83, compared to 1760486400 on 5754980. Therefore, it implies a Short% of Shares Outstanding of 6575260 and a Short% of Float of 3.25.
Earnings Estimates
. The current assessment of Amneal Pharmaceuticals Inc (AMRX) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.19, with high estimates of $0.21 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.82 and $0.78 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $0.94, with 4.0 analysts recommending between $1.03 and $0.89.
Revenue Estimates
4 analysts predict $808.14M in revenue for. The current quarter. It ranges from a high estimate of $822.7M to a low estimate of $790.11M. As of. The current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $730.52MFor the next quarter, 4 analysts are estimating revenue of $741.79M. There is a high estimate of $748.71M for the next quarter, whereas the lowest estimate is $728.7M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $3.03B, while the lowest revenue estimate was $2.99B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.79BBased on 4 analysts’ estimates, the company’s revenue will be $3.21B in the next fiscal year. The high estimate is $3.23B and the low estimate is $3.18B.
